New malaria vaccine trial aims to block infection without causing illness
NCT ID NCT06862453
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new malaria vaccine (PfSPZ-LARC2) in 58 healthy adults who have never had malaria. The vaccine uses weakened malaria parasites that stop growing in the liver and cannot cause blood infection. Researchers will check if it is safe and if it protects against malaria when volunteers are later exposed to the parasite.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA,FALCIPARUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Tubingen
RECRUITINGTübingen, D-72074, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental malaria vaccine aims to block parasite growth
- New malaria drug interaction study launches in healthy volunteers
- New malaria shots could replace daily pills
- New malaria antibody enters first human safety tests
- Breastfeeding moms with malaria: do drugs reach baby?
- New malaria pill shows promise in early trial